RXRX vs RLAY
RXRX and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | — | $3.61B |
| Revenue growth (YoY) | 26.9% | — |
| Earnings growth (YoY) | -39.1% | — |
| EBIT margin | -867.9% | — |
| ROE | -62.9% | — |
| ROIC | -174.7% | — |
| 1y total return | -49.6% | — |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RXRX vs RLAY
| Metric | RXRX | RLAY |
|---|---|---|
| End value | $958 | $5.8K |
| Total return | -90.4% | -42.2% |
| CAGR | -35.8% | -9.9% |
| Volatility | 92.9% | 77.2% |
| Sharpe | -0.08 | 0.20 |
| Sortino | -0.12 | 0.30 |
| Max drawdown | -93.1% | -94.7% |
Based on 1329 common trading days, 2021-04-16 → 2026-07-31 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)